You searched for "cytology"
Benign upper tract abnormalities
Case 1 A 28-year-old lady has been referred to your clinic with right loin pain. She has no significant past medical history but mentions that she and her partner have been trying to get pregnant. She has an US renal...Management of lower urinary tract foreign bodies
Of all the urological emergencies presenting to the emergency department, perhaps one of the most technically challenging cases is the patient with a foreign body in the genitourinary (GU) tract. A wide variety of GU foreign bodies have been reported...Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...Uropathology: what’s the diagnosis?
Case 1 A 28-year-old man presented with a left testicular mass. Tumour markers were taken and he went on to have a radical inguinal orchidectomy. The specimen and histology are shown. Which testicular tumour markers were taken? What does their...
Oncological Imaging: Urology
Imaging updates on renal tumours, urothelial tumours, prostate, adrenal and retroperitoneal tumours are all covered in this text. Whilst aspects relating to prostate imaging are probably covered better elsewhere, what remains is a decent account nicely contained within a single...PROSPACKS supports prostate cancer patients starting treatment in Scotland
Men across Scotland undergoing treatment for prostate cancer can benefit from new care and support packs thanks to a project by charity Prostate Scotland and long-term funder, the Grand Lodge of Scotland. PROSPACKS – tailored packs for men beginning radiotherapy,...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
